These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 25515657)

  • 1. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials.
    van Soest RJ; Templeton AJ; Vera-Badillo FE; Mercier F; Sonpavde G; Amir E; Tombal B; Rosenthal M; Eisenberger MA; Tannock IF; de Wit R
    Ann Oncol; 2015 Apr; 26(4):743-749. PubMed ID: 25515657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel.
    Nuhn P; Vaghasia AM; Goyal J; Zhou XC; Carducci MA; Eisenberger MA; Antonarakis ES
    BJU Int; 2014 Dec; 114(6b):E11-E17. PubMed ID: 24529213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use.
    Lorente D; Mateo J; Templeton AJ; Zafeiriou Z; Bianchini D; Ferraldeschi R; Bahl A; Shen L; Su Z; Sartor O; de Bono JS
    Ann Oncol; 2015 Apr; 26(4):750-755. PubMed ID: 25538172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.
    Meisel A; von Felten S; Vogt DR; Liewen H; de Wit R; de Bono J; Sartor O; Stenner-Liewen F
    Eur J Cancer; 2016 Mar; 56():93-100. PubMed ID: 26829012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study.
    van Soest RJ; de Morrée ES; Shen L; Tannock IF; Eisenberger MA; de Wit R
    Eur Urol; 2014 Aug; 66(2):330-6. PubMed ID: 23957945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors of first-line docetaxel treatment in castration-resistant prostate cancer: roles of neutrophil-to-lymphocyte ratio in patients from Northwestern China.
    Pei XQ; He DL; Tian G; Lv W; Jiang YM; Wu DP; Fan JH; Wu KJ
    Int Urol Nephrol; 2017 Apr; 49(4):629-635. PubMed ID: 28161841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy.
    Halabi S; Lin CY; Small EJ; Armstrong AJ; Kaplan EB; Petrylak D; Sternberg CN; Shen L; Oudard S; de Bono J; Sartor O
    J Natl Cancer Inst; 2013 Nov; 105(22):1729-37. PubMed ID: 24136890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of an inflammatory index for patients with metastatic castration-resistant prostate cancer.
    Yamada Y; Sakamoto S; Rii J; Yamamoto S; Kamada S; Imamura Y; Nakamura K; Komiya A; Nakatsu H; Ichikawa T
    Prostate; 2020 May; 80(7):559-569. PubMed ID: 32134137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.
    Sonpavde G; Pond GR; Armstrong AJ; Clarke SJ; Vardy JL; Templeton AJ; Wang SL; Paolini J; Chen I; Chow-Maneval E; Lechuga M; Smith MR; Michaelson MD
    Clin Genitourin Cancer; 2014 Oct; 12(5):317-24. PubMed ID: 24806399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data.
    Guinney J; Wang T; Laajala TD; Winner KK; Bare JC; Neto EC; Khan SA; Peddinti G; Airola A; Pahikkala T; Mirtti T; Yu T; Bot BM; Shen L; Abdallah K; Norman T; Friend S; Stolovitzky G; Soule H; Sweeney CJ; Ryan CJ; Scher HI; Sartor O; Xie Y; Aittokallio T; Zhou FL; Costello JC;
    Lancet Oncol; 2017 Jan; 18(1):132-142. PubMed ID: 27864015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
    Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer.
    Jang HS; Koo KC; Cho KS; Chung BH
    Yonsei Med J; 2016 Sep; 57(5):1070-8. PubMed ID: 27401636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio.
    Templeton AJ; Pezaro C; Omlin A; McNamara MG; Leibowitz-Amit R; Vera-Badillo FE; Attard G; de Bono JS; Tannock IF; Amir E
    Cancer; 2014 Nov; 120(21):3346-52. PubMed ID: 24995769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance).
    Aggarwal R; Halabi S; Kelly WK; George D; Mahoney JF; Millard F; Stadler WM; Morris MJ; Kantoff P; Monk JP; Carducci M; Small EJ;
    Cancer; 2013 Oct; 119(20):3636-43. PubMed ID: 23913744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment outcome of docetaxel plus prednisolone for metastatic castration-resistant prostate cancer in Korea.
    Cho IC; Joung JY; Seo HK; Chung J; Park WS; Lee KH
    J Cancer Res Ther; 2014; 10(2):251-7. PubMed ID: 25022374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).
    Mehra N; Dolling D; Sumanasuriya S; Christova R; Pope L; Carreira S; Seed G; Yuan W; Goodall J; Hall E; Flohr P; Boysen G; Bianchini D; Sartor O; Eisenberger MA; Fizazi K; Oudard S; Chadjaa M; Macé S; de Bono JS
    Eur Urol; 2018 Sep; 74(3):283-291. PubMed ID: 29500065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive setting.
    Gebrael G; Hage Chehade C; Sayegh N; Tripathi N; Chigarira B; Goel D; Nordblad B; McFarland TR; Narang A; Srivastava A; Tandar C; Dal E; Jo Y; Galarza Fortuna G; Mathew Thomas V; Sahu KK; Li H; Maughan BL; Swami U; Agarwal N
    Prostate; 2024 Jun; 84(9):888-892. PubMed ID: 38561317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study.
    de Wit R; Wülfing C; Castellano D; Kramer G; Eymard JC; Sternberg CN; Fizazi K; Tombal B; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Foster MC; Ozatilgan A; Geffriaud-Ricouard C; de Bono J
    ESMO Open; 2021 Oct; 6(5):100241. PubMed ID: 34450475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial.
    Chi KN; Higano CS; Blumenstein B; Ferrero JM; Reeves J; Feyerabend S; Gravis G; Merseburger AS; Stenzl A; Bergman AM; Mukherjee SD; Zalewski P; Saad F; Jacobs C; Gleave M; de Bono JS
    Lancet Oncol; 2017 Apr; 18(4):473-485. PubMed ID: 28283282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.